A Phase 2, Randomized, Double-Blind, Active-Controlled, Dose-Finding Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants Given 4 Doses at 2, 4, 6, and 12-15 Months of Age Concomitantly with Routine Pediatr

Project: Research project

Project Details

StatusActive
Effective start/end date3/11/25 → 3/10/30

Funding

  • Vaxcyte Inc ( Award # ): $13,500.00